Related Experiment Video
Updated: May 28, 2026

A Semi-Automated and Reproducible Biological-Based Method to Quantify Calcium Deposition In Vitro
Published on: June 2, 2022
Association Between Serum SFRP1 Levels and Coronary Artery Calcification in Stage 5D Chronic Kidney Disease
1Hebei Clinical Research Center for Chronic Kidney Disease, Hebei Key Laboratory of Vascular Calcification in Kidney Disease, Department of Nephrology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Insights
Elevated serum Secreted Frizzled-Related Protein 1 (SFRP1) levels are linked to coronary artery calcification (CAC) in patients with Stage 5D chronic kidney disease (CKD) on maintenance hemodialysis (MHD). SFRP1 may serve as a biomarker for identifying at-risk individuals.
Area of Science:
- Nephrology
- Cardiology
- Biochemistry
Background:
- Patients with Stage 5D chronic kidney disease (CKD) undergoing maintenance hemodialysis (MHD) have a high prevalence of cardiovascular disease, particularly coronary artery calcification (CAC).
- Secreted Frizzled-Related Protein 1 (SFRP1) is a protein that plays a role in Wnt signaling, which is implicated in vascular calcification.
- The association between SFRP1 levels and CAC in this specific patient population remains under-investigated.
Purpose of the Study:
- To investigate the association between serum SFRP1 levels and the presence and severity of CAC in patients with Stage 5D CKD on MHD.
- To identify potential biomarkers for predicting CAC in this high-risk group.
Main Methods:
- A case-control study was conducted with 76 patients undergoing MHD.
- Patients were stratified into non-calcified, low-score calcification, and high-score calcification groups based on Coronary Artery Calcium Scores (CACS).
- Serum SFRP1 and various biochemical parameters were measured; correlation and multivariate linear regression analyses were performed.
Main Results:
- Coronary artery calcification (CAC) was present in 60.5% of the study population.
- Serum SFRP1 concentrations were significantly higher in patients with high-score CAC compared to other groups (p < 0.01).
- SFRP1 and phosphorus levels were identified as independent risk factors for CAC (p < 0.05), with SFRP1 demonstrating a high predictive value (AUC = 0.898).
Conclusions:
- Elevated serum SFRP1 levels are significantly associated with an increased likelihood and severity of CAC in patients with Stage 5D CKD on MHD.
- SFRP1 emerges as a potential novel biomarker for early detection and risk stratification of CAC in this vulnerable patient cohort.
- Further research is warranted to explore the therapeutic implications of targeting SFRP1 in CKD-related cardiovascular complications.
Abstract:
This study aimed to examine the association between serum Secreted Frizzled-Related Protein 1 (SFRP1) levels and the presence of coronary artery calcification (CAC) in patients with Stage 5D chronic kidney disease (CKD) undergoing maintenance hemodialysis (MHD). A case-control study was conducted involving 76 patients with CKD Stage 5D undergoing MHD. Participants were stratified into three groups based on Coronary Artery Calcium Scores (CACS): non-calcified (CACS < 100), low-score calcification (100 ? CACS ? 400), and high-score calcification (CACS > 400). Serum concentrations of SFRP1, hemoglobin, albumin, ferritin, C-reactive protein (CRP), calcium, phosphorus, 25-hydroxyvitamin D, and intact parathyroid hormone were measured. Correlations between biochemical parameters and CAC were evaluated, and multivariate linear regression analysis was employed to identify independent risk factors for CAC. CAC was detected in 60.5 % of the study population. Serum SFRP1 concentrations were significantly elevated in the high-score calcification group compared to both the low-score and non-calcified groups, with the lowest levels observed in the non-calcified group (p < 0.01). Positive correlations were observed between CAC and serum levels of SFRP1 levels, phosphorus, age, hemoglobin, alkaline phosphatase, and age. Multivariate linear regression analysis identified serum SFRP1 and phosphorus levels as independent risk factors for CAC in this population (p < 0.05). Receiver operating characteristic (ROC) curve analysis demonstrated that serum SFRP1 levels yielded an area under the curve (AUC) of 0.898 (95 % CI: 0.826-0.970, p < 0.0001) for predicting CAC, with a Youden index of 0.738 at a cut-off value of 4.242 ng/ml. Elevated serum SFRP1 levels were associated with an increased likelihood of CAC in patients with Stage 5D CKD undergoing MHD. These findings suggest that SFRP1 may represent a potential biomarker for identifying patients at risk for CAC in this population.
Related Concept Videos
Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
Chronic Kidney Disease III: Interprofessional Care
Chronic Kidney Disease I: Introduction
Chronic Kidney Disease II: Clinical Manifestations
Drug Dosing in Renal Diseases: Measurement of Glomerular Filtration Rate
